Behçet's disease: A new target for anti-tumour necrosis factor treatment

Annals of the Rheumatic Diseases

Volumn 61, Issue SUPPL. 2, 2002, Pages

  Sfikakis, P P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOTHERAPY; INFLAMMATORY DISEASE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYNOVITIS; THROMBOPHLEBITIS; UVEITIS; VASCULITIS;

EID: 0036838908     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.suppl_2.ii51     Document Type: Conference Paper

References (29)

1. Kaklamani VG, Valopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum 1998;27:197-217.
2. Yazici H, Behçet's syndrome: Where do we stand? Am J Med 2002;112:75-6.
3. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
4. Yardacul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001;44:2686-92.
5. Hamaryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome. A randomized, double blind, placebo controlled trial. Ann Intern Med 1998;128:443-50.
6. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322:281-5.
7. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease: An update. Semin Arthritis Rheum 2001;30:299-312.
8. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989;i:1093-6.
9. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin-A versus pulsed cyclophospamide Behçet's syndrome: A single-masked trial. Br J Ophthalmol 1992;76:241-3.
10. Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994;118:723-9.
11. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet's disease: A randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71.
12. Kotter I, Eckstein AK, Stubiger N, Zierhut M. Treatment of ocular symptoms of Behçet's disease with Interferon alfa-2a: A pilot study. Br J Ophthalmol 1998;82:488-94.
13. Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of Interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 2000;8:293-301.
14. Gul A. Behçet's disease: An update on the pathogenesis. Clin Exp Rheumatol 2001;19 (suppl 24):S6-12.
15. Yamashita N, Kaneoka H, Kaneko S, et al. Role of gammadelta T lymphocytes in the development of Behçet's disease. Clin Exp Immunol 1997;107:241-7.
16. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte-derive TNF-a, IL-6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993;20:1544-9.
17. Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24:128-32.
18. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-a, sIL-2R, OL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002;11:87-93
19. Chronopoulou H, Tzavara V, Oikonomopoulos N, et al. High levels of TNF-a in the in the aqueous humor in patients suffering from Adamantiades-Behçet's disease: preliminary results. Invest Ophthalmol Vis Sci 2001;42 (suppl 4):S708
20. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001;33:251-5.
21. Goossens PH, Verburg RI, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor a blocking therapy. Ann Rheum Dis 2001;60:637.
22. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with Infliximab. Rheumatology 2001;40:473-4.
23. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report. Gastroenterology 2001;120:995-9.
24. Travis SP, SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumor necrosis factor alpha antibody. Gut 2001;49:725-8.
25. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 2001;358:1644.
26. Rosenbaum M, Rosner I, Portnoy E. Remission of Behçet's syndrome with TNFa blocking treatment. Ann Rheum Dis 2002;61:283-4.
27. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-6.
28. Nussenblatt RB. Uveitis in Behçet's disease. Int Rev Immunol 1997;14:67-9.
29. van Deventer SJH. Transmembrane TNF-a, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001;121:1242-5.